Axl and EGFR Dual-Specific Binding Affibody for Targeted Therapy in Nasopharyngeal Carcinoma
Cells · 2024
DOI: 10.3390/cells13221823 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Saidu Kamara und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Virology and Immunology, Department of Microbiology and Immunology, School of Basic Medical Sciences, Wenzhou Medical Universi…. Hauptthemen laut MEDLINE: Nasopharyngeal Carcinoma, ErbB Receptors, Receptor Protein-Tyrosine Kinases, Proto-Oncogene Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Nature Science Foundation of China.
Abstract (Originalsprache)
Nasopharyngeal carcinoma (NPC) is a tumor of the head and neck, with a higher incidence in southern China and Southeast Asia. Radiotherapy and chemotherapy are the main treatments; however, metastasis and recurrence remain the main causes of treatment failure. Further, the majority of patients are diagnosed in the late stage due to lack of tumor-specific biomarker for early diagnosis. Therefore, an effective treatment and early detection can improve the outcome of patient with NPC. Axl and EGFR are co-expressed in NPC tissues and play key roles in tumor proliferation, migration, and invasion, which are often correlated with poor prognosis and therapy resistance. In this study, we generated a novel bispecific affibody (Z239-1907) for the dual targeting and inhibition of Axl and EGFR expression in NPC-positive cells both in vitro and in vivo. The in vitro experiments demonstrated that Z239-1907 had more pronounced antitumor effects than either modality alone (ZAXL239 or ZEGFR1907) in NPC-positive cells. Further, mice bearing NPC-positive tumors showed significant inhibition in tumor growth after treatment with Z239-1907 compared to ZAXL239 and ZEGFR1907. The in vivo tumor targeting ability and imaging also showed that Z239-1907 specifically and selectively targeted NPC xenograft mice models and accumulate at tumor site as early as 30 min and disappeared within 24 h post-injection. Collectively, these results suggest that Z239-1907 dual-target affibody is a promising therapeutic agent and a molecular imaging probe for early diagnosis in NPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Molecular Virology and Immunology, Department of Microbiology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
Förderung
- National Nature Science Foundation of China
Zitieren
APA
Kamara, S., Wen, H., Guo, Y., Liu, Y., Liu, L., Du, W., Chen, J., Zhu, S., & Zhang, L. (2024). Axl and EGFR Dual-Specific Binding Affibody for Targeted Therapy in Nasopharyngeal Carcinoma. Cells. https://doi.org/10.3390/cells13221823
Vancouver
Kamara S, Wen H, Guo Y, Liu Y, Liu L, Du W, et al. Axl and EGFR Dual-Specific Binding Affibody for Targeted Therapy in Nasopharyngeal Carcinoma. Cells. 2024. doi:10.3390/cells13221823
BibTeX
@article{Kamara2024,
author = {Kamara, Saidu and Wen, He and Guo, Yanru and Liu, Ying and Liu, Lei and Du, Wangqi and Chen, Jun and Zhu, Shanli and Zhang, Lifang},
title = {Axl and EGFR Dual-Specific Binding Affibody for Targeted Therapy in Nasopharyngeal Carcinoma},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13221823}
}
EUVIMED